Arecor Therapeutics strikes deal for development of peptide therapy

(Alliance News) - Arecor Therapeutics PLC on Wednesday said it has partnered with an unnamed ...

Alliance News 12 March, 2025 | 3:34PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Arecor Therapeutics PLC on Wednesday said it has partnered with an unnamed biopharmaceutical company to develop a novel formulation of peptide therapy.

The Cambridgeshire, England-based biopharmaceutical company said the clinical-stage firm that develops peptide therapies would fund Arecor's development activities, with the option to then license the rights to the new formulation, to further develop and commercialise the product.

Arecor said it will develop the therapy using its proprietary technology platform, Arestat.

"Peptides are an increasingly important class of therapeutics to treat a wide range of chronic conditions," said Chief Executive Officer Sarah Howell.

"Arecor's significant expertise in developing novel formulations of therapeutic peptides to address unmet patient needs in this large and growing market. This collaboration further validates our leadership in this field."

The global peptide therapeutics market is forecast to reach more than USD100 billion by 2034, at a compound annual growth rate of 10.8%, Arecor also noted.

Arecor continues to progress its development of oral versions of its peptide therapies, including its initial oral glucagon-like peptide-1 receptor against programme, which would provide patients an alternative to the usual injectable treatments.

Shares in Arecor Therapeutics were up 3.6% at 52.30 pence each in London on Wednesday afternoon. The stock remains down 61% over the past year.

By Emily Parsons, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Arecor Therapeutics PLC Ordinary Shares 50.50 GBX 0.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures